Anixa Biosciences Inc (ANIX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 10-31. Amounts in USD.

Revenue Quarterly

-300K 0 300K 600K 900K Q3 '17: 362.5K Q4 '17: 0 Q1 '18: 0 Q2 '18: 750K Q3 '18: 362.5K Q4 '18: 0 Q1 '19: 0 Q2 '19: 250K Q3 '19: 0 Q4 '19: 0 Q1 '21: 513K Q2 '21: 0 Q3 '21: 0 Q4 '21: -1K Q1 '22: 513K Q2 '22: 0 Q1 '23: 0 Q2 '23: 210K Q3 '23: 0 Q4 '23: 0 Q4 '17 Q3 '18 Q2 '19 Q1 '21 Q4 '21 Q1 '23 Q4 '23

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -4.4M Q4 '21: -4.1M Q1 '22: -3.9M Q2 '22: -3.6M Q3 '22: -2.8M Q4 '22: -3.6M Q1 '23: -2.6M Q2 '23: -2.6M Q3 '23: -2.8M Q4 '23: -3.1M Q1 '24: -3.6M Q2 '24: -3.5M Q3 '24: -3.6M Q4 '24: -3.2M Q1 '25: -3.4M Q2 '25: -3M Q3 '25: -2.4M Q4 '25: -2.9M Q1 '26: -2.7M Q2 '26: -2.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -4.3M Q4 '21: -4M Q1 '22: -3.8M Q2 '22: -3.5M Q3 '22: -2.7M Q4 '22: -3.5M Q1 '23: -2.3M Q2 '23: -2.3M Q3 '23: -2.5M Q4 '23: -2.7M Q1 '24: -3.3M Q2 '24: -3.1M Q3 '24: -3.3M Q4 '24: -2.9M Q1 '25: -3.2M Q2 '25: -2.8M Q3 '25: -2.3M Q4 '25: -2.7M Q1 '26: -2.6M Q2 '26: -2.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-3M -2M -1M 0 1M 2M 3M Q3 '21: -1.5M Q4 '21: -1M Q1 '22: -1.2M Q2 '22: -2.3M Q3 '22: -1.4M Q4 '22: -1.6M Q1 '23: -2M Q2 '23: -807K Q3 '23: -1.4M Q4 '23: -2M Q1 '24: -2.3M Q2 '24: -1.5M Q3 '24: -2.6M Q4 '24: -927K Q1 '25: -2.9M Q2 '25: -1.5M Q3 '25: -1.5M Q4 '25: -1.3M Q1 '26: -2.6M Q2 '26: -1.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q3 '15: -708.5K Q4 '15: -801.9K Q1 '16: -638.4K Q2 '16: -1.4M Q3 '16: -818.2K Q4 '16: -684.9K Q1 '17: -744K Q2 '17: -1.1M Q3 '17: -1.3M Q4 '17: -752.6K Q1 '18: -1.3M Q2 '18: -751.8K Q3 '18: -1.2M Q4 '18: -1M Q3 '19: -640.1K Q4 '19: -1.3M Q1 '20: -1.9M Q2 '20: -1.6M Q3 '20: -1.3M Q4 '20: -1.4M Q4 '15 Q3 '16 Q2 '17 Q1 '18 Q4 '18 Q1 '20 Q4 '20

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '16: 8.7M Q2 '17: 9.7M Q2 '18: 16.7M Q1 '21: 25.2M Q2 '21: 28.7M Q3 '21: 30.5K Q1 '22: 30.1K Q2 '22: 30.2K Q3 '22: 30.5K Q1 '23: 30.9K Q2 '23: 30.9K Q3 '23: 31K Q1 '24: 31.4M Q2 '24: 31.9M Q3 '24: 32.1M Q1 '25: 32.2M Q2 '25: 32.2M Q3 '25: 32.5M Q1 '26: 33.2M Q2 '26: 33.6M Q2 '17 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.05 -0.70 -0.35 0.00 0.35 0.70 1.05 Q3 '18: -0.60 Q4 '18: -0.78 Q1 '19: -0.92 Q2 '19: -0.97 Q3 '19: -0.78 Q4 '19: -0.59 Q1 '20: -0.47 Q2 '20: -0.46 Q3 '20: -0.46 Q4 '20: -0.45 Q1 '21: -0.41 Q2 '21: -0.37 Q3 '24: -0.39 Q4 '24: -0.39 Q1 '25: -0.39 Q2 '25: -0.38 Q3 '25: -0.35 Q4 '25: -0.35 Q1 '26: -0.33 Q2 '26: -0.31 Q4 '18 Q3 '19 Q2 '20 Q1 '21 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.